APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rheumatic Disorders Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rheumatic Disorders Drug Market Outlook and Growth Opportunities 2026

Report ID 174032760422 December 2025194 pages

Choose your research edition.

Industry ResearchRheumatic Disorders Drug Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Rheumatic Disorders Drug Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Rheumatic Disorders Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rheumatic Disorders Drug Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Rheumatic Disorders Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Rheumatic Disorders Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rheumatic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rheumatic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rheumatic Disorders Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rheumatic Disorders Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rheumatic Disorders Drug market include Bristol-Myers Squibb, AbbVie, Amgen, Pfizer, Eli Lilly, Roche, Novartis and Johnson & Johnson, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Rheumatic Disorders Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rheumatic Disorders Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rheumatic Disorders Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Rheumatic Disorders Drug market.

Rheumatic Disorders Drug Segment by Company

Bristol-Myers Squibb

AbbVie

Amgen

Pfizer

Eli Lilly

Roche

Novartis

Johnson & Johnson

Rheumatic Disorders Drug Segment by Type

Acting on Interleukins and Interleukin Receptors

Acting on Protein Kinases

Acting on Hormones and Hormone Receptors

Acting on Cell Surface Antigens

Acting on Tumor Necrosis Factor-Alpha

Others

Rheumatic Disorders Drug Segment by Application

Psoriatic Arthritis

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Osteoporosis

Osteoarthritis

Others

Rheumatic Disorders Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rheumatic Disorders Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Rheumatic Disorders Drug key companies, revenue, market share, and recent developments.

3. To split the Rheumatic Disorders Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Rheumatic Disorders Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rheumatic Disorders Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Rheumatic Disorders Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatic Disorders Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rheumatic Disorders Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatic Disorders Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rheumatic Disorders Drug industry.

Chapter 3: Detailed analysis of Rheumatic Disorders Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Rheumatic Disorders Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Rheumatic Disorders Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rheumatic Disorders Drug Industry Trends Table 2. Rheumatic Disorders Drug Industry Drivers Table 3. Rheumatic Disorders Drug Industry Opportunities and Challenges Table 4. Rheumatic Disorders Drug Industry Restraints Table 5. Global Rheumatic Disorders Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rheumatic Disorders Drug Revenue Share by Company (2021-2026) Table 7. Global Rheumatic Disorders Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Rheumatic Disorders Drug Key Company Manufacturing Base & Headquarters Table 9. Global Rheumatic Disorders Drug Company, Product Type & Application Table 10. Global Rheumatic Disorders Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Rheumatic Disorders Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Acting on Interleukins and Interleukin Receptors Table 15. Significant Companies of Acting on Protein Kinases Table 16. Significant Companies of Acting on Hormones and Hormone Receptors Table 17. Significant Companies of Acting on Cell Surface Antigens Table 18. Significant Companies of Acting on Tumor Necrosis Factor-Alpha Table 19. Significant Companies of Others Table 20. Global Rheumatic Disorders Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Rheumatic Disorders Drug Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Rheumatic Disorders Drug Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Rheumatic Disorders Drug Sales Value Share by Type (2021-2026) Table 24. Global Rheumatic Disorders Drug Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Psoriatic Arthritis Table 26. Significant Companies of Systemic Lupus Erythematosus Table 27. Significant Companies of Rheumatoid Arthritis Table 28. Significant Companies of Osteoporosis Table 29. Significant Companies of Osteoarthritis Table 30. Significant Companies of Others Table 31. Global Rheumatic Disorders Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Rheumatic Disorders Drug Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Rheumatic Disorders Drug Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Rheumatic Disorders Drug Sales Value Share by Application (2021-2026) Table 35. Global Rheumatic Disorders Drug Sales Value Share by Application (2027-2032) Table 36. Global Rheumatic Disorders Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Rheumatic Disorders Drug Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Rheumatic Disorders Drug Sales Value Share by Region (2021-2026) Table 39. Global Rheumatic Disorders Drug Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Rheumatic Disorders Drug Sales Value Share by Region (2027-2032) Table 41. Global Rheumatic Disorders Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Rheumatic Disorders Drug Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Rheumatic Disorders Drug Sales Value Market Share by Country (2021-2026) Table 44. Global Rheumatic Disorders Drug Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Rheumatic Disorders Drug Sales Value Market Share by Country (2027-2032) Table 46. Bristol-Myers Squibb Company Information Table 47. Bristol-Myers Squibb Business Overview Table 48. Bristol-Myers Squibb Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Bristol-Myers Squibb Rheumatic Disorders Drug Product Portfolio Table 50. Bristol-Myers Squibb Recent Development Table 51. AbbVie Company Information Table 52. AbbVie Business Overview Table 53. AbbVie Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. AbbVie Rheumatic Disorders Drug Product Portfolio Table 55. AbbVie Recent Development Table 56. Amgen Company Information Table 57. Amgen Business Overview Table 58. Amgen Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Amgen Rheumatic Disorders Drug Product Portfolio Table 60. Amgen Recent Development Table 61. Pfizer Company Information Table 62. Pfizer Business Overview Table 63. Pfizer Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Pfizer Rheumatic Disorders Drug Product Portfolio Table 65. Pfizer Recent Development Table 66. Eli Lilly Company Information Table 67. Eli Lilly Business Overview Table 68. Eli Lilly Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Eli Lilly Rheumatic Disorders Drug Product Portfolio Table 70. Eli Lilly Recent Development Table 71. Roche Company Information Table 72. Roche Business Overview Table 73. Roche Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Roche Rheumatic Disorders Drug Product Portfolio Table 75. Roche Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Novartis Rheumatic Disorders Drug Product Portfolio Table 80. Novartis Recent Development Table 81. Johnson & Johnson Company Information Table 82. Johnson & Johnson Business Overview Table 83. Johnson & Johnson Rheumatic Disorders Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Johnson & Johnson Rheumatic Disorders Drug Product Portfolio Table 85. Johnson & Johnson Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Rheumatic Disorders Drug Product Image Figure 2. Global Rheumatic Disorders Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rheumatic Disorders Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Rheumatic Disorders Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Acting on Interleukins and Interleukin Receptors Image Figure 8. Acting on Protein Kinases Image Figure 9. Acting on Hormones and Hormone Receptors Image Figure 10. Acting on Cell Surface Antigens Image Figure 11. Acting on Tumor Necrosis Factor-Alpha Image Figure 12. Others Image Figure 13. Global Rheumatic Disorders Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Rheumatic Disorders Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Rheumatic Disorders Drug Sales Value Share by Type (2021-2032) Figure 16. Psoriatic Arthritis Image Figure 17. Systemic Lupus Erythematosus Image Figure 18. Rheumatoid Arthritis Image Figure 19. Osteoporosis Image Figure 20. Osteoarthritis Image Figure 21. Others Image Figure 22. Global Rheumatic Disorders Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Rheumatic Disorders Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Rheumatic Disorders Drug Sales Value Share by Application (2021-2032) Figure 25. Global Rheumatic Disorders Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Rheumatic Disorders Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Rheumatic Disorders Drug Sales Value (2021-2032) & (US$ Million) Figure 28. North America Rheumatic Disorders Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Rheumatic Disorders Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Rheumatic Disorders Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Rheumatic Disorders Drug Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Rheumatic Disorders Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Rheumatic Disorders Drug Sales Value (2021-2032) & (US$ Million) Figure 34. South America Rheumatic Disorders Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Rheumatic Disorders Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Rheumatic Disorders Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Acting on Interleukins and Interleukin Receptors
  • Acting on Protein Kinases
  • Acting on Hormones and Hormone Receptors
  • Acting on Cell Surface Antigens
  • Acting on Tumor Necrosis Factor-Alpha
  • Others
Applications
  • Psoriatic Arthritis
  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis
  • Osteoporosis
  • Osteoarthritis
  • Others
Companies covered
  • Bristol-Myers Squibb
  • AbbVie
  • Amgen
  • Pfizer
  • Eli Lilly
  • Roche
  • Novartis
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rheumatic Disorders Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rheumatic Disorders Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Rheumatic Disorders Drug Market Dynamics
  1. 2.1 Rheumatic Disorders Drug Industry Trends
  2. 2.2 Rheumatic Disorders Drug Industry Drivers
  3. 2.3 Rheumatic Disorders Drug Industry Opportunities and Challenges
  4. 2.4 Rheumatic Disorders Drug Industry Restraints
3 Rheumatic Disorders Drug Market by Company
  1. 3.1 Global Rheumatic Disorders Drug Company Revenue Ranking in 2025
  2. 3.2 Global Rheumatic Disorders Drug Revenue by Company (2021-2026)
  3. 3.3 Global Rheumatic Disorders Drug Company Ranking (2024-2026)
  4. 3.4 Global Rheumatic Disorders Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Rheumatic Disorders Drug Company Product Type and Application
  6. 3.6 Global Rheumatic Disorders Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Rheumatic Disorders Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Rheumatic Disorders Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Rheumatic Disorders Drug Market by Type
  1. 4.1 Rheumatic Disorders Drug Type Introduction
  2. 4.1.1 Acting on Interleukins and Interleukin Receptors
  3. 4.1.2 Acting on Protein Kinases
  4. 4.1.3 Acting on Hormones and Hormone Receptors
  5. 4.1.4 Acting on Cell Surface Antigens
  6. 4.1.5 Acting on Tumor Necrosis Factor-Alpha
  7. 4.1.6 Others
  8. 4.2 Global Rheumatic Disorders Drug Sales Value by Type
  9. 4.2.1 Global Rheumatic Disorders Drug Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Rheumatic Disorders Drug Sales Value by Type (2021-2032)
  11. 4.2.3 Global Rheumatic Disorders Drug Sales Value Share by Type (2021-2032)
5 Rheumatic Disorders Drug Market by Application
  1. 5.1 Rheumatic Disorders Drug Application Introduction
  2. 5.1.1 Psoriatic Arthritis
  3. 5.1.2 Systemic Lupus Erythematosus
  4. 5.1.3 Rheumatoid Arthritis
  5. 5.1.4 Osteoporosis
  6. 5.1.5 Osteoarthritis
  7. 5.1.6 Others
  8. 5.2 Global Rheumatic Disorders Drug Sales Value by Application
  9. 5.2.1 Global Rheumatic Disorders Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Rheumatic Disorders Drug Sales Value by Application (2021-2032)
  11. 5.2.3 Global Rheumatic Disorders Drug Sales Value Share by Application (2021-2032)
6 Rheumatic Disorders Drug Regional Value Analysis
  1. 6.1 Global Rheumatic Disorders Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rheumatic Disorders Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Rheumatic Disorders Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Rheumatic Disorders Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rheumatic Disorders Drug Sales Value (2021-2032)
  7. 6.3.2 North America Rheumatic Disorders Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Rheumatic Disorders Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Rheumatic Disorders Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Rheumatic Disorders Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Rheumatic Disorders Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Rheumatic Disorders Drug Sales Value (2021-2032)
  16. 6.6.2 South America Rheumatic Disorders Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Rheumatic Disorders Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Rheumatic Disorders Drug Sales Value Share by Country, 2025 VS 2032
7 Rheumatic Disorders Drug Country-level Value Analysis
  1. 7.1 Global Rheumatic Disorders Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rheumatic Disorders Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Rheumatic Disorders Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Rheumatic Disorders Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Rheumatic Disorders Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Rheumatic Disorders Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Rheumatic Disorders Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb
  2. 8.1.1 Bristol-Myers Squibb Company Information
  3. 8.1.2 Bristol-Myers Squibb Business Overview
  4. 8.1.3 Bristol-Myers Squibb Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Rheumatic Disorders Drug Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Rheumatic Disorders Drug Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Rheumatic Disorders Drug Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Rheumatic Disorders Drug Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Rheumatic Disorders Drug Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Rheumatic Disorders Drug Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Rheumatic Disorders Drug Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Johnson & Johnson
  44. 8.8.1 Johnson & Johnson Company Information
  45. 8.8.2 Johnson & Johnson Business Overview
  46. 8.8.3 Johnson & Johnson Rheumatic Disorders Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson & Johnson Rheumatic Disorders Drug Product Portfolio
  48. 8.8.5 Johnson & Johnson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst